CancerMyo-EXERTBCNCT07698314
A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
A study testing Conditioning Resistance Training, Strength Resistance Training and Hypertrophy Resistance Training in people with Cancer and Breast Cancer, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) at 2 sites in United States.
Trial summary
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens. Read more about this study
- Who is it for?
- Ages 20 to 89 years, women only
- Conditions the study is for
- Cancer, Breast Cancer
- What is being tested?
- Conditioning Resistance Training, Strength Resistance Training and Hypertrophy Resistance Training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 2 sitesUnited States
- Study dates
- 6 Jul 2026to Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 89 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
Who cannot join
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Pregnant women
- Males
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Not yet recruiting
AHN Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Clinical Trials Contact, 412-330-6151, clinicaltrials@ahn.org
- Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Clinical Trials Contact, 4123306151, ctgov@ahn.org
About this study
Official title: Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
- Conditions
- Cancer, Breast Cancer
- Being tested
- Conditioning Resistance Training, Strength Resistance Training, Hypertrophy Resistance Training
- Medical subject headings
- Neoplasms, Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conditioning Resistance TrainingBehavioural
Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training".
Strength Resistance TrainingBehavioural
Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8".
Hypertrophy Resistance TrainingBehavioural
Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm".
| Study group | Role | What they receive |
|---|---|---|
| Conditioning Regimen Group | Experimental | Not described Receives: Behavioral: Conditioning Resistance Training |
| Strength Regimen Group | Experimental | Not described Receives: Behavioral: Strength Resistance Training |
| Hypertrophy Regimen Group | Experimental | Not described Receives: Behavioral: Hypertrophy Resistance Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Myokine Production After First Exercise Session
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined.
Measured: Immediately before and immediately after the first exercise session.
Change in Myokine Production After Final Exercise Session of Each Week
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined.
Measured: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
Change in Myokine Production After Final Exercise Session of the Month (End of Study)
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined.
Measured: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start6 Jul 2026
- Primary completionJul 2027 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 21 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Colin Champ, MD, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Investigators
- Colin Champ, MD, Principal investigator, AHN Radiation Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07698314
- Sponsor's protocol ID
- 2026-125
- Acronym
- Myo-EXERTBC
- Status last verified
- Sep 2026
- First submitted
- 7 Jul 2026
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
- ClinicalTrials.gov ID
- NCT07698314
- Acronym / sponsor ID
- Myo-EXERTBC / 2026-125
- Conditions
- Cancer, Breast Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 21 participants (estimated)
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)University, hospital or other
- Study start
- 6 Jul 2026 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Conditioning Regimen Group | Experimental | Behavioral: Conditioning Resistance Training |
| Strength Regimen Group | Experimental | Behavioral: Strength Resistance Training |
| Hypertrophy Regimen Group | Experimental | Behavioral: Hypertrophy Resistance Training |
Who may qualify
- Ages
- 20 to 89 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
Key exclusion criteria (5 listed)
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Pregnant women
- Males
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conditioning Resistance TrainingParticipants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training". | Behavioural | Conditioning Regimen Group |
| Strength Resistance TrainingParticipants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8". | Behavioural | Strength Regimen Group |
| Hypertrophy Resistance TrainingParticipants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm". | Behavioural | Hypertrophy Regimen Group |
Primary outcome
Change in Myokine Production After First Exercise Session
Time frame: Immediately before and immediately after the first exercise session.
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined.
Change in Myokine Production After Final Exercise Session of Each Week
Time frame: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined.
Change in Myokine Production After Final Exercise Session of the Month (End of Study)
Time frame: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
Related trials for Cancer
RecruitingPhase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Not yet recruiting
Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening
Breast Cancer Screening, Breast Cancer Awareness
Not yet recruiting
The AYA Oncology Self-care Movement
Acute Lymphobkastic Leukemia, Medication Adherence
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Colin Champ, MD principal investigator
AHN Radiation Oncology
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conditioning Resistance Training, Strength Resistance Training and Hypertrophy Resistance Training in people with Cancer and Breast Cancer, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Trials Contact (412-330-6151, ctgov@ahn.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Myokine Production After First Exercise Session (time frame: Immediately before and immediately after the first exercise session.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.